|
|
|
|
LEADER |
02571nam a2200301Ia 4500 |
001 |
10.3892-mco.2022.2560 |
008 |
220718s2022 CNT 000 0 und d |
020 |
|
|
|a 20499450 (ISSN)
|
245 |
1 |
0 |
|a Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study
|
260 |
|
0 |
|b Spandidos Publications
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.3892/mco.2022.2560
|
520 |
3 |
|
|a The present study aimed to investigate the relationship between BMI and the prostate cancer (PCa) risk at biopsy in Italian men. Retrospective analyses of the clinical data of 2,372 consecutive men undergoing ultrasound-guided multicore (≥10) prostate biopsy transrectally between May 2010 and December 2018 were performed. BMIs were categorized, according to Western countries' classification of obesity, as follows: <18. 5 kg/m2 (underweight), 18. 5-24.99 kg/m2 (normal weight), 25-30 kg/m2 (overweight) and >30 kg/m2 (obese). The distribution of patients undergoing biopsy was compared with a model population from the official survey data. Patient characteristics and the relationships between characteristics were investigated using correlation analysis, ANOVA, Kruskal-Wallis and Dunn's tests. The present study estimated the influence on cancer incidence not only of BMI but also of other patient characteristics using multi-variable logistic modelling and compared, using the models, the expected outcomes for patients who differed only in BMI. From a sample of 2,372 men, the present study enrolled 1,079 men due to a lack of clinical data [such as prostate specific antigen (PSA) and BMI data] in the other patients undergoing prostate biopsy. Their distribution was significantly different from the model distribution with the probability of undergoing biopsy increasing with increasing BMI. The median age was 69.4 years. The median BMI was 26.4 kg/m2, while the median. © 2022, Spandidos Publications. All rights reserved.
|
650 |
0 |
4 |
|a body mass index
|
650 |
0 |
4 |
|a high-grade prostatic disease
|
650 |
0 |
4 |
|a prostate cancer
|
700 |
1 |
|
|a Baio, R.
|e author
|
700 |
1 |
|
|a Caruana, C.
|e author
|
700 |
1 |
|
|a D'angelo, C.
|e author
|
700 |
1 |
|
|a Di Mauro, U.
|e author
|
700 |
1 |
|
|a Francavilla, A.B.
|e author
|
700 |
1 |
|
|a Guarnaccia, C.
|e author
|
700 |
1 |
|
|a Intilla, O.
|e author
|
700 |
1 |
|
|a Molisso, G.
|e author
|
700 |
1 |
|
|a Napodano, G.
|e author
|
700 |
1 |
|
|a Pane, U.
|e author
|
700 |
1 |
|
|a Pentimalli, F.
|e author
|
700 |
1 |
|
|a Sanseverino, R.
|e author
|
773 |
|
|
|t Molecular and Clinical Oncology
|